GO:0005338 nucleotide-sugar transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005338 describes the molecular function of moving nucleotide-sugars across cellular membranes, a process essential for glycosylation, cell wall synthesis, and extracellular matrix formation.
• Nucleotide-sugar transporters (NSTs) are polytopic membrane proteins belonging to the drug/metabolite transporter (DMT) superfamily and the solute carrier family 35 (SLC35).
• These transporters typically function as antiporters, exchanging a nucleotide-sugar for the corresponding nucleoside monophosphate (e.g., UDP-galactose for UMP).
• Key residues, such as conserved glutamate and lysine, are critical for substrate recognition and antiport activity, as shown for Slc35a3.
• NSTs are implicated in human diseases including cancer, developmental disorders, and glycosylation defects, making them potential therapeutic targets.
• CRISPR-based knockout, point mutation, and knock-in models are powerful tools to dissect the physiological roles of individual NSTs.
Description
Nucleotide-sugar transmembrane transporter activity (GO:0005338) is a molecular function that enables the transfer of nucleotide-sugars from one side of a membrane to the other. Nucleotide-sugars are activated forms of monosaccharides, such as UDP-galactose, UDP-glucose, and CMP-sialic acid, which serve as donors for glycosyltransferases in the lumen of the endoplasmic reticulum (ER) and Golgi apparatus. This transport activity is essential for protein glycosylation, glycolipid synthesis, and the production of extracellular matrix components. Researchers study these transporters to understand fundamental cell biology and their roles in human disease, including cancer and congenital disorders of glycosylation. The transporters are polytopic membrane proteins that often function as antiporters, coupling the import of a nucleotide-sugar with the export of a nucleoside monophosphate. This article provides a comprehensive overview of the mechanism, key genes, and research methods for studying GO:0005338.
nucleotide-sugar transmembrane transporter activity At A Glance
| GO ID | GO:0005338 |
|---|---|
| GO term | nucleotide-sugar transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Transports nucleotide-sugars across membranes, essential for glycosylation and cell wall synthesis. |
| Protein family | Drug/metabolite transporter (DMT) superfamily; solute carrier family 35 (SLC35). |
| Substrates | UDP-galactose, UDP-glucose, UDP-N-acetylglucosamine, CMP-sialic acid, GDP-mannose, etc.. |
| Mechanism | Antiport with nucleoside monophosphates (e.g., UMP). |
| Cellular location | Endoplasmic reticulum and Golgi apparatus membranes. |
What Is GO:0005338?
GO:0005338, nucleotide-sugar transmembrane transporter activity, is defined as the transfer of a nucleotide-sugar from one side of a membrane to the other. A nucleotide-sugar is any nucleotide in which the distal phosphoric residue of a nucleoside 5'-diphosphate is in glycosidic linkage with a monosaccharide or monosaccharide derivative. This activity is typically mediated by integral membrane proteins that facilitate the movement of these hydrophilic molecules across lipid bilayers, often against a concentration gradient, using an antiport mechanism.
Why Is nucleotide-sugar transmembrane transporter activity Important in Cell Biology?
Nucleotide-sugar transmembrane transporter activity is fundamental to glycosylation, a process that modifies proteins and lipids and is critical for cell-cell communication, immune recognition, and structural integrity. Defects in these transporters lead to a range of human diseases, including cancer, developmental disorders, and glycosylation defects. Understanding their function provides insights into basic cell biology and offers potential targets for therapeutic intervention.
• Essential for protein glycosylation, affecting protein folding, stability, and function.
• Required for the synthesis of glycolipids and extracellular matrix components.
• Mutations in NSTs cause congenital disorders of glycosylation and other developmental defects.
• Altered expression of NSTs is associated with cancer progression and metastasis.
• NSTs are potential drug targets for cancer and infectious diseases.
• They play a role in plant cell wall biosynthesis and anthocyanin accumulation.
• NSTs are involved in the regulation of immune responses through glycosylation of immune receptors.
• Studying NSTs helps understand the molecular basis of substrate specificity and transport mechanisms.
What Happens During nucleotide-sugar transmembrane transporter activity?
Substrate Recognition and Binding
In simple terms: The transporter recognizes and grabs the specific nucleotide-sugar it needs to move.
Nucleotide-sugar transporters (NSTs) exhibit high specificity for their substrates, which is determined by the amino acid residues in their transmembrane domains. For example, the Golgi UDP-galactose transporter specifically recognizes UDP-galactose, and mutations in its transmembrane domains abolish transport activity. Conserved residues, such as Glu-47 and Lys-50 in Slc35a3, are critical for substrate binding and antiport activity. The binding site likely involves a combination of hydrogen bonding and electrostatic interactions with the nucleotide and sugar moieties.
Antiport Mechanism
In simple terms: The transporter swaps the nucleotide-sugar for a different molecule, usually a nucleoside monophosphate, to move it across the membrane.
Most NSTs function as antiporters, exchanging a nucleotide-sugar for a nucleoside monophosphate. For instance, the Golgi UDP-galactose transporter imports UDP-galactose into the Golgi lumen in exchange for UMP. Similarly, Slc35a3 mediates the antiport of UDP-N-acetylglucosamine and UMP. This exchange mechanism ensures a continuous supply of nucleotide-sugars for glycosylation reactions while removing the inhibitory nucleoside monophosphate byproducts.
Conformational Changes and Transport Cycle
In simple terms: The transporter changes shape to shuttle the molecule from one side of the membrane to the other.
NSTs undergo conformational changes during the transport cycle, alternating between outward-facing and inward-facing states. The binding of the substrate induces a conformational shift that allows the substrate to be translocated across the membrane. The transport cycle is completed by the binding and export of the counter-substrate. The detailed structural basis of these conformational changes is an active area of research, with homology to other DMT superfamily members providing insights.
Regulation of Transport Activity
In simple terms: The activity of the transporter can be turned up or down depending on the cell's needs.
NST activity can be regulated at multiple levels, including transcriptional regulation and post-translational modifications. For example, the sweetpotato NST IbSLC35F1 is transcriptionally activated by IbMYB1, modulating anthocyanin accumulation. In mammals, the expression of NSTs can be induced by cellular stress or during differentiation. Additionally, the transport activity can be influenced by the availability of substrates and the membrane environment.
Key Genes Involved in GO:0005338 nucleotide-sugar transmembrane transporter activity
The following table lists key genes encoding nucleotide-sugar transmembrane transporters and their research relevance.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC35A1 | CMP-sialic acid transporter | Mutations cause congenital disorder of glycosylation; studied for Golgi transport. |
| SLC35A2 | UDP-galactose transporter | Defects lead to developmental disorders; model for substrate specificity. |
| SLC35A3 | UDP-N-acetylglucosamine transporter | Critical residues for antiport identified; linked to arthrogryposis. |
| SLC35B1 | Broad di- and tri-nucleotide exchanger | Transports ATP across ER membrane; roles in ER homeostasis. |
| SLC35C1 | GDP-fucose transporter | Defects cause leukocyte adhesion deficiency type II. |
| SLC35D1 | UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter | Involved in proteoglycan synthesis; mutations cause Schneckenbecken dysplasia. |
| SLC35D2 | UDP-N-acetylglucosamine transporter | Plays a role in glycosaminoglycan biosynthesis. |
| SLC35E1 | Putative nucleotide-sugar transporter | Associated with cancer progression. |
| SLC35F1 | Nucleotide sugar transporter | Modulates anthocyanin accumulation in sweetpotato. |
| UGT1 | UDP-galactose transporter | Rice homolog; transports UDP-galactose and UDP-glucose. |
| UGT2 | UDP-galactose transporter | Rice homolog; involved in cell wall synthesis. |
| HAD-1 | UDP-galactose transporter | Murine mutant used to study Golgi transport defects. |
| GONST1 | GDP-mannose transporter | Plant Golgi transporter; affects cell wall composition. |
| AtUTr1 | UDP-glucose/UDP-galactose transporter | Arabidopsis ER transporter; stress response. |
| Slc35a3 | UDP-N-acetylglucosamine/UMP antiporter | Mouse model for Golgi transport studies. |
| IbSLC35F1 | Nucleotide sugar transporter | Transcriptional regulation by MYB; anthocyanin pathway. |
How Is nucleotide-sugar transmembrane transporter activity Regulated?
Nucleotide-sugar transmembrane transporter activity is regulated at the transcriptional level by transcription factors such as IbMYB1, which activates IbSLC35F1 in sweetpotato. Post-translational modifications and substrate availability also influence transport activity. Additionally, the expression of NSTs can be modulated by cellular stress and differentiation signals.
nucleotide-sugar transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC35A1 | Congenital disorder of glycosylation type IIf | Knockout HEK293 cells; patient-derived fibroblasts. |
| SLC35A2 | Congenital disorder of glycosylation type IIm | Knockout mouse models; iPSC-derived neurons. |
| SLC35C1 | Leukocyte adhesion deficiency type II | Knockout mice; HL-60 cells. |
| SLC35D1 | Schneckenbecken dysplasia | Zebrafish knockout; chondrocyte cultures. |
| SLC35E1 | Cancer progression | Cancer cell lines with overexpression/knockdown. |
Congenital Disorders of Glycosylation
Mutations in nucleotide-sugar transporters cause congenital disorders of glycosylation (CDG), a group of rare inherited metabolic diseases. For example, defects in SLC35A1 (CMP-sialic acid transporter) lead to CDG type IIf, characterized by developmental delay and coagulation abnormalities. SLC35A2 mutations cause CDG type IIm, with seizures and hypotonia. SLC35C1 defects result in leukocyte adhesion deficiency type II, featuring recurrent infections and neutrophilia. These disorders highlight the critical role of NSTs in human health.
Cancer
Altered expression of nucleotide-sugar transporters is associated with cancer progression. For instance, SLC35E1 is implicated in cancer, and its expression correlates with tumor aggressiveness. Glycosylation changes mediated by NSTs affect cell adhesion, migration, and immune evasion, contributing to metastasis. Targeting NSTs may offer therapeutic strategies for cancer treatment.
Developmental and Skeletal Disorders
Mutations in SLC35D1, a UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter, cause Schneckenbecken dysplasia, a severe skeletal dysplasia characterized by short limbs and a snail-like pelvis. This underscores the importance of NSTs in cartilage and bone development.
From nucleotide-sugar transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the substrate specificity of a novel NST? | Knockout cell lines complemented with wild-type or mutant transporter. |
| How does a point mutation affect transport activity? | Point mutation knock-in using CRISPR in HEK293 or HeLa cells. |
| What are the physiological consequences of NST loss? | Knockout mouse models or zebrafish. |
| Where is the transporter localized? | Tagged knock-in with fluorescent protein (e.g., GFP). |
| Does overexpression of NST alter glycosylation? | Overexpression cell lines and glycomic analysis. |
| Can we rescue a disease phenotype by restoring NST function? | Knock-in of wild-type gene in patient-derived cells. |
How to Study the nucleotide-sugar transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive transport assay | Uptake of nucleotide-sugars into membrane vesicles | Determining kinetic parameters and substrate specificity. |
| Mass spectrometry | Glycan structures and composition | Assessing glycosylation defects in knockout cells. |
| Lectin blotting | Specific glycan epitopes | Rapid screening for glycosylation changes. |
| Fluorescence microscopy | Subcellular localization of tagged transporters | Confirming ER/Golgi localization. |
| CRISPR knockout screen | Genes required for glycosylation or transport | Identifying novel NSTs and related factors. |
| Site-directed mutagenesis | Effect of point mutations on transport activity | Mapping critical residues. |
| Heterologous expression | Functional characterization of transporters | Studying plant or pathogen NSTs in yeast or mammalian cells. |
| Proteomics | Protein interactions and post-translational modifications | Identifying regulatory partners. |
Transport Assays
Transport assays using radioactive or fluorescent nucleotide-sugars are used to measure the activity of NSTs. For example, the uptake of UDP-galactose into Golgi vesicles can be quantified. These assays help determine kinetic parameters and substrate specificity.
Glycosylation Analysis
Changes in glycosylation patterns can be assessed by mass spectrometry, lectin blotting, or HPLC. Knockout of NSTs often leads to altered glycan structures, which can be detected using these methods.
Imaging and Localization
Fluorescence microscopy of tagged transporters (e.g., GFP-fusion) reveals their subcellular localization in the ER or Golgi. Co-localization with organelle markers confirms their distribution.
Genetic and CRISPR Screens
CRISPR knockout screens can identify genes required for glycosylation or transport. For example, a genome-wide screen for resistance to lectins can uncover NSTs. Such screens are powerful for discovering new components of the glycosylation machinery.
How CRISPR Can Be Used to Study GO:0005338 nucleotide-sugar transmembrane transporter activity
Knockout
CRISPR knockout of NST genes in cell lines (e.g., HEK293, HeLa) abolishes transport activity, leading to glycosylation defects. These models are used to study the physiological roles of individual transporters and to identify compensatory mechanisms.
Point Mutation
Point mutations in NST genes can be introduced using CRISPR to mimic disease-associated mutations. For example, mutating conserved residues like Glu-47 or Lys-50 in SLC35A3 abolishes antiport activity, providing insights into the transport mechanism.
Knock-in
Knock-in of tagged versions of NSTs (e.g., GFP or HA) allows visualization and purification of the transporter. This approach is useful for localization studies and interaction proteomics.
Overexpression
Overexpression of NSTs in cell lines can enhance glycosylation capacity and is used to study substrate specificity and regulation. For example, overexpression of IbSLC35F1 in sweetpotato increased anthocyanin accumulation.
How EDITGENE Supports nucleotide-sugar transmembrane transporter activity Research
Researchers studying nucleotide-sugar transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation, development, or disease. EDITGENE provides comprehensive CRISPR-based services to accelerate this research, from knockout to knock-in models.
Contact EDITGENE today to design your custom CRISPR model for nucleotide-sugar transmembrane transporter activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLC35D2 Knockout HEK293 Cell Line | EDJ-KQ7258 | Human | 11046 | Details Get a Quote |
| SLC35E3 Knockout HEK293 Cell Line | EDJ-KQ15329 | Human | 55508 | Details Get a Quote |
| SLC35E3 Knockout A-549 Cell Line | EDJ-KQ46047 | Human | 55508 | Details Get a Quote |
| SLC35E3 Knockout HCT 116 Cell Line | EDJ-KQ46048 | Human | 55508 | Details Get a Quote |
| SLC35E3 Knockout HeLa Cell Line | EDJ-KQ46049 | Human | 55508 | Details Get a Quote |
| SLC35D2 Knockout A-549 Cell Line | EDJ-KQ32265 | Human | 11046 | Details Get a Quote |
| SLC35D2 Knockout HCT 116 Cell Line | EDJ-KQ32266 | Human | 11046 | Details Get a Quote |
| SLC35D2 Knockout HeLa Cell Line | EDJ-KQ32267 | Human | 11046 | Details Get a Quote |
Frequently Asked Questions About nucleotide-sugar transmembrane transporter activity
What is nucleotide-sugar transmembrane transporter activity?
It is a molecular function (GO:0005338) that enables the movement of nucleotide-sugars, such as UDP-galactose, across cellular membranes, typically in exchange for a nucleoside monophosphate.
What genes are involved in nucleotide-sugar transmembrane transporter activity?
Genes include SLC35A1, SLC35A2, SLC35A3, SLC35B1, SLC35C1, SLC35D1, and plant homologs like UGT1 and GONST1.
What diseases are associated with defects in nucleotide-sugar transporters?
Mutations cause congenital disorders of glycosylation (e.g., SLC35A1, SLC35A2), leukocyte adhesion deficiency type II (SLC35C1), and Schneckenbecken dysplasia (SLC35D1).
How do nucleotide-sugar transporters work?
Most function as antiporters, exchanging a nucleotide-sugar for a nucleoside monophosphate, such as UDP-galactose for UMP.
Where are nucleotide-sugar transporters located?
They are integral membrane proteins primarily located in the endoplasmic reticulum and Golgi apparatus.
What is the role of SLC35A3?
SLC35A3 is a Golgi UDP-N-acetylglucosamine transporter; conserved residues Glu-47 and Lys-50 are critical for its antiport activity.
Can CRISPR be used to study nucleotide-sugar transporters?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to dissect their functions and disease relevance.
What methods are used to measure nucleotide-sugar transport?
Radioactive transport assays, mass spectrometry, lectin blotting, and fluorescence microscopy are common methods.
Are there plant nucleotide-sugar transporters?
Yes, plant NSTs such as UGT1 and GONST1 transport UDP-galactose and GDP-mannose, respectively, and are important for cell wall synthesis.
How is nucleotide-sugar transporter activity regulated?
Regulation occurs at transcriptional and post-translational levels; for example, IbMYB1 activates IbSLC35F1 in sweetpotato.
Conclusion
Nucleotide-sugar transmembrane transporter activity (GO:0005338) is a fundamental molecular function required for glycosylation and numerous cellular processes. Dysregulation of these transporters leads to a spectrum of human diseases, including congenital disorders of glycosylation and cancer. Advances in CRISPR-based models and analytical methods continue to unravel their mechanisms and therapeutic potential. EDITGENE offers comprehensive services to support research in this field, from gene editing to bioinformatics.
References
- 1. Jack DL et al.. 2001. The drug/metabolite transporter superfamily.. Eur J Biochem 268(13):3620-39 PMID: 11432728
- 2. Gerardy-Schahn R et al.. 2001. Nucleotide sugar transporters: biological and functional aspects.. Biochimie 83(8):775-82 PMID: 11530210
- 3. Seino J et al.. 2010. Characterization of rice nucleotide sugar transporters capable of transporting UDP-galactose and UDP-glucose.. J Biochem 148(1):35-46 PMID: 20305274
- 4. Lan M et al.. 2026. Sweetpotato solute carrier family 35 member F1 (IbSLC35F1), a nucleotide sugar transporter transcriptionally activated by IbMYB1, modulates anthocyanin accumulation in storage roots.. Int J Biol Macromol 339(Pt 2):150076 PMID: 41485669
- 5. Schwarzbaum PJ et al.. 2022. The broad range di- and tri-nucleotide exchanger SLC35B1 displays asymmetrical affinities for ATP transport across the ER membrane.. J Biol Chem 298(4):101537 PMID: 35041824
- 6. Ishida N et al.. 1999. Indispensability of transmembrane domains of Golgi UDP-galactose transporter as revealed by analysis of genetic defects in UDP-galactose transporter-deficient murine had-1 mutant cell lines and construction of deletion mutants.. J Biochem 126(6):1107-17 PMID: 10578063
- 7. Toscanini MA et al.. 2019. Conserved Glu-47 and Lys-50 residues are critical for UDP-N-acetylglucosamine/UMP antiport activity of the mouse Golgi-associated transporter Slc35a3.. J Biol Chem 294(26):10042-10054 PMID: 31118275
- 8. Eckhardt M et al.. 1999. Membrane topology of the mammalian CMP-sialic acid transporter.. J Biol Chem 274(13):8779-87 PMID: 10085119
